Weekly, paclitaxel plus carboplatin in patients with metastatic transitional cell carcinoma of the urothelium who failed MVAC: Phase II trial

被引：0
|
作者：
Kouno, T. [1 ]
Ando, M. [1 ]
Yonemori, K. [1 ]
Matsumoto, K. [1 ]
Komiyama, M. [1 ]
Okajima, E. [1 ]
Matsuoka, N. [1 ]
Fujimoto, H. [1 ]
Fujiwara, Y. [1 ]
机构：
[1] Natl Canc Ctr, Div Med Oncol, Tokyo, Japan
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：246 / 247
页数：2
相关论文
共 50 条
  • [41] Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer
    Loesch, D
    Robert, N
    Asmar, L
    Gregurich, MA
    O'Rourke, M
    Dakhil, S
    Cox, E
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3857 - 3864
  • [42] Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract
    Pycha, A
    Grbovic, M
    Posch, B
    Schnack, B
    Haitel, A
    Heinz-Peer, G
    Zielinski, CC
    Marberger, M
    UROLOGY, 1999, 53 (03) : 510 - 515
  • [43] Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer
    Takayama, Koichi
    Ichiki, Masao
    Tokunaga, Shoji
    Inoue, Koji
    Kawasaki, Masayuki
    Uchino, Junji
    Nakanishi, Yoichi
    ONCOLOGIST, 2019, 24 (11): : 1420 - +
  • [44] Phase II trial of paclitaxel plus doxorubicin plus carboplatin in patients with intermediate risk, high risk, or recurrent endometrial carcinoma
    Shoji, T.
    Kurachi, H.
    Tabata, T.
    Kigawa, J.
    Nishimura, S.
    Hosokawa, K.
    Suzuki, M.
    Hatae, M.
    Shiozawa, T.
    Sugiyama, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
    Rivkin, Saul E.
    Iriarte, Desiree
    Sloan, Heather
    Wiseman, Cara
    Moon, James
    Goodman, Gary E.
    Bondurant, Amy
    Veljovich, Daniel
    Jiang, Peter Y. Z.
    Wahl, Tanya A.
    Shah, Chirag
    Drescher, Charles
    Kaplan, Henry G.
    Peters, William A.
    Ellis, Erin
    Fer, Mehmet F.
    Park, Min S.
    Johnston, Eileen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] A multicenter phase I-II trial of weekly paclitaxel and carboplatin plus bevacizumab in women with triple-negative metastatic breast cancer
    Saloustros, Emmanouil S.
    Polyzos, Aristidis
    Christophyllakis, Charalampos
    Kentepozidis, Nikolaos K.
    Vamvakas, Lampros
    Kalbakis, Kostas
    Agelaki, Sofia
    Georgoulias, Vassilis
    Mavroudis, Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] A phase II trial of gemcitabine and carboplatin (GC) in patients with transitional cell carcinoma of the urinary tract (TCC).
    Olivares, J
    Hyman, W
    Senzer, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 404S - 404S
  • [48] Final Results of Sequential Doxorubicin Plus Gemcitabine and Ifosfamide, Paclitaxel, and Cisplatin Chemotherapy in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium
    Milowsky, Matthew I.
    Nanus, David M.
    Maluf, Fernando C.
    Mironov, Svetlana
    Shi, Weiji
    Iasonos, Alexia
    Riches, Jamie
    Regazzi, Ashley
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4062 - 4067
  • [49] Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma - A phase II trial using a triplet combination
    Leong, SS
    Wee, J
    Tay, MH
    Toh, CK
    Tan, SB
    Thng, CH
    Foo, KF
    Lim, WT
    Tan, T
    Tan, EH
    CANCER, 2005, 103 (03) : 569 - 575
  • [50] A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer
    Cowherd, S.
    Miller, L. D.
    Melin, S. A.
    Akman, S.
    Isom, S.
    Cole, J.
    Pullikuth, A.
    Lawrence, J. A.
    CANCER BIOLOGY & THERAPY, 2015, 16 (05) : 678 - 683
12345